Next Article in Journal
The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice
Next Article in Special Issue
Development of Bactericidal Peptides against Multidrug-Resistant Acinetobacter baumannii with Enhanced Stability and Low Toxicity
Previous Article in Journal
Mechanisms Affecting Physical Aging and Swelling by Blending an Amphiphilic Component
Previous Article in Special Issue
Real-Time Fluorescence Microscopy on Living E. coli Sheds New Light on the Antibacterial Effects of the King Penguin β-Defensin AvBD103b
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 4
10.3390/ijms23042164
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective against Candida spp. Clinical Isolates

by
Francesca Bugli
1,2,†,
Federica Massaro
3,†,
Francesco Buonocore
3,
Paolo Roberto Saraceni
3,
Stefano Borocci
3,4,
Francesca Ceccacci
5,
Cecilia Bombelli
5,
Maura Di Vito
1,
Rosalba Marchitiello
1,
Melinda Mariotti
1,
Riccardo Torelli
2,
Maurizio Sanguinetti
1,2,* and
Fernando Porcelli
3,*
1
Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
2
Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A, Gemelli IRCCS, 00168 Rome, Italy
3
Department for Innovation in Biological, Agrofood and Forest Systems, University of Tuscia, 01100 Viterbo, Italy
4
CNR—Institute for Biological Systems, Area Della Ricerca di Roma 1, SP35d 9, 00010 Montelibretti, Italy
5
CNR—Institute For Biological Systems, Sede Secondaria di Roma-Meccanismi di Reazione, c/o Università La Sapienza, 00185 Rome, Italy
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2022, 23(4), 2164; https://doi.org/10.3390/ijms23042164
Submission received: 26 January 2022 / Revised: 10 February 2022 / Accepted: 12 February 2022 / Published: 16 February 2022
(This article belongs to the Special Issue Antimicrobial Peptides: Structure and Mechanism of Biological Activity)
Browse Figures
Review Reports Versions Notes

Abstract

:
The increasing resistance of fungi to antibiotics is a severe challenge in public health, and newly effective drugs are required. Promising potential medications are lipopeptides, linear antimicrobial peptides (AMPs) conjugated to a lipid tail, usually at the N-terminus. In this paper, we investigated the in vitro and in vivo antifungal activity of three short myristoylated and non-myristoylated peptides derived from a mutant of the AMP Chionodracine. We determined their interaction with anionic and zwitterionic membrane-mimicking vesicles and their structure during this interaction. We then investigated their cytotoxic and hemolytic activity against mammalian cells. Lipidated peptides showed a broad spectrum of activity against a relevant panel of pathogen fungi belonging to Candida spp., including the multidrug-resistant C. auris. The antifungal activity was also observed vs. biofilms of C. albicans, C. tropicalis, and C. auris. Finally, a pilot efficacy study was conducted on the in vivo model consisting of Galleria mellonella larvae. Treatment with the most-promising myristoylated peptide was effective in counteracting the infection from C. auris and C. albicans and the death of the larvae. Therefore, this myristoylated peptide is a potential candidate to develop antifungal agents against human fungal pathogens.

1. Introduction

In recent years, extensive abuse of chemicals to control diseases has been associated with the increasing number of multidrug-resistant pathogens. The growth of fungi and bacteria resistant to conventional antimicrobial agents represents one of the biggest concerns worldwide [1,2,3,4].
Systemic fungal infections are challenging and represent a significant cause of morbidity and mortality, especially for immune-compromised people. Fungi infect billions of people every year, with a high rate of mortality of about 1.5 million [1]. Pathogenic fungi, like human cells, are eukaryotic, and potential selective drugs can only attack limited targets. Many antifungal drugs act on the biosynthetic pathway of ergosterol, the functional analog of cholesterol in animal cells, essential for regulating membrane fluidity, or on the cell wall component 1,3-β-D-glucan, or internal components, such as fungal nucleic acids [2,3]. However, the only licensed antifungal therapies for humans, polyenes, azoles, echinocandins, and flucytosine, suffer several limitations due to cross-target toxicity. Thus, the need for more effective and less toxic antifungal agents is irrefutable. Antimicrobial peptides (AMPs), which are key components of the innate immune system [4], are ubiquitously present in vertebrates, invertebrates, plants, and bacteria and represent promising antifungal candidates. In 1948, Bacillomycin, the first AMP with antifungal activity, was isolated from the bacteria Bacillus subtilis [5] and, in recent years, others were evidenced [6,7].
An important class of AMP is constituted in its mature form by 15–50 amino acid residues; they are generally cationic and adopt an amphipathic structure upon interacting with the microbial negatively charged membrane. α-helices and β-sheets are the most common secondary structures they adopt [8,9,10]. AMPs typically kill pathogens by disrupting the cell membrane with consequent leakage of internal material [11], but they also could enter the pathogen cell and reach an intracellular target [12,13]. Moreover, AMPs can represent a valid alternative to overcome the antimicrobial resistance to conventional antibiotics because they are less susceptible to the evolution of resistance in microorganisms [14,15]. However, most studies on AMPs are focused on their antibacterial properties and not on their antifungal activity. Interestingly, AMPs could also prevent fungal biofilm formation or eradicate preformed biofilms; their efficacy has been associated with different mechanisms of action, such as cell wall perturbation, the inhibition of cell adhesion onto surfaces, and interaction with other targets inside fungal cells [16].
An interesting approach to increase the antifungal activity of AMPs is to conjugate small peptides with fatty acids of different lengths. Natural lipopeptides, produced in bacteria and fungi, are usually composed of a fatty acid chain conjugated to a short linear or cyclic peptide. In 2003, the Food and Drug Administration (FDA) approved CubicinR (Daptomycin) as the first cyclic lipopeptide antibiotic for the treatment of severe infections caused by Gram-positive bacteria, despite its toxicity [17]. The proposed mechanism of action involves cyclic chain insertion into the cell membrane with consequent depolarization and ionic efflux. Various studies demonstrated that the conjugation of a cationic linear antimicrobial peptide with a fatty acid chain could improve its antimicrobial and antifungal activity [18,19,20,21]. Indeed, lipopeptides with positively charged residues retain the amphipathic structure typical of AMPs, and the presence of the hydrophobic tail enhances their surface-active properties.
In this paper, starting from the template of KHS-Cnd, a 22-amino-acid residue mutant of the AMP Chionodracine [22], we designed a series of 11-residue peptides. The three peptides WFGKLYRGITK (Pep-A), WRGITKVVKKV (Pep-B), and WVVKKVKGLLK (Pep-C) have been conjugated at the N-terminus with myristic acid to obtain three lipopeptides, Myr-WFGKLYRGITK (Myr-A), Myr-WRGITKVVKKV (Myr-B), and Myr-WVVKKVKGLLK (Myr-C). All the peptides have been characterized by CD spectroscopy, and their self-assembly properties have been elucidated. Molecular dynamics (MD) simulations were carried out to investigate, with an atomic resolution, the interaction of myristoylated and non-myristoylated peptides with a zwitterionic membrane model (POPC) and an anionic membrane model (POPC/POPG). Furthermore, studies carried out with membrane-mimicking systems revealed the ability of lipopeptides to interact with both zwitterionic and anionic membranes, evidencing a preference for the latter. Moreover, we determined their antifungal, hemolytic, and cytotoxic activities. Specifically, we proved the antifungal activity against a relevant panel of pathogenic fungi belonging to Candida spp., and biofilms formed by C. albicans, C. tropicalis, and C. auris. Finally, the more active lipopeptide was used in a pilot study on an in vivo model consisting of Galleria mellonella larvae infected with C. auris. The tested lipopeptide was effective in counteracting infection and death of the larvae.

2. Results and Discussion

2.1. Peptide Design and Physico-Chemical Properties

The first step in the activity and selectivity of cationic AMPs is the electrostatic interaction with the negatively charged bacterial membrane [23,24,25]. Thus, different strategies are used to improve the antibacterial activity with the aim to create more efficient potential agents in clinical. The most-used approach is to find the correct balance between the net positive charge and the amphipathic properties to obtain peptides that can fold in α-helices or β-structures [22,26,27,28]. In the present study, we designed small peptides derived from the sequence of KHS-Cnd [22]. KHS-Cnd was chosen because of its high antimicrobial activity against Gram-positive, Gram-negative, and multidrug-resistant bacteria and relatively low cytotoxicity. We synthesized three small peptides of 11 amino acids from the parental peptide. The sequences and physicochemical properties of the three derivatives corresponding to the N-terminal, central, and C-terminal portions of KHS-Cnd, named Pep-A, Pep-B, and Pep-C, are reported in Table 1. Many studies report that the functionalization with fatty acid chains increases antifungal activity [20,21]. Thus, we modified the N-terminal by introducing a hydrophobic myristoyl moiety (14-carbon fatty acid) to favor the vehiculation and interaction of peptides with membranes and enhance their membrane-anchoring properties [29,30]. This modification increased the hydrophobicity of peptides without varying the peptide sequence.
Physico-chemical properties of myristoylated peptides, called Myr-A, Myr-B, and Myr-C, are also reported in Table 1.

2.2. Critical Micellar Concentration (CMC) Determination

Lipopeptides usually self-assemble in organized structures that have attracted interest because of their enhanced bactericidal and fungicidal effects [31,32]. The self-assembly of myristoylated peptides was evaluated by determining the critical micellar concentration (CMC) that represents the concentration of spontaneous associations of monomers by a spectrofluorometric method. 8-anilinonaphtalene-1-sulfonate (ANS) was used as a fluorescent probe since its fluorescence is very sensitive to the microenvironment, showing a blue shift and intensity increase upon changing from a polar to non-polar medium [33]. Therefore, the fluorescence of ANS was monitored as a function of the lipopeptide concentration. Figure 1A shows the emission spectra of ANS at increasing concentrations of myristoylated peptides (Myr-C). Figure 1B shows the plot of fluorescence intensity of ANS (the maximum emission wavelength was 465 nm) vs. the logarithm of the lipidated peptide concentration. Fluorescence intensity slowly increases up to a certain lipopeptide concentration and then breaks abruptly, indicating a sudden change in the aggregation state of lipopeptides. For each peptide, the critical micellar concentration (CMC) was evaluated by the intersection of the two lines. The values of CMC are 4.7 ± 0.8 μM, 5.1 ± 0.8 μM, and 5.1 ± 0.4 μM for Myr-A, Myr-B, and Myr-C, respectively (data for Myr-A and Myr-B are reported in Supplementary Information Figures S1 and S2).
Non-lipidated peptides did not show a break in the fluorescence intensity upon titration, suggesting that they do not aggregate.

2.3. Membrane Partition Studies

To quantify the interaction of different lipidated and non-lipidated peptides with membrane mimetic systems, we measured the intrinsic fluorescence of Trp-1 upon partition with LUVs (large unilamellar vesicles) of different compositions. Briefly, the mixtures of POPC/POPG (70%/30% w/w) LUVs were used to mimic anionic membranes and POPC only to mimic zwitterionic membranes [34,35,36]. LUVs do not entirely describe the complexity of natural membranes; still, they are used here to evaluate the preference of different peptides for anionic (bacteria and fungi) and zwitterionic (mammalian cell) membranes. The mole fraction partition constants Kx were calculated from the partition isotherms as previously described [37]. Figure 2 reports the partition isotherms for the titration of myristoylated and non-myristoylated peptides with POPC and POPC/POPG vesicles.
The values of Kx for all peptides are reported in Table 2 together with ΔG values, calculated using the expression ΔG = −RT lnKx, and the selectivity ratio defined as the ratio between partition constants determined in anionic and zwitterionic membranes. Higher values of the selectivity ratio represent a preference of the peptide for anionic vesicles, while lower values indicate a preference for the zwitterionic one.
Partitioning data suggest that myristoylated peptides interact with LUVs with higher affinity. The mole fraction partition coefficients Kx range from 3.0 × 104 to 5.2 × 104 with calculated Gibbs free energies of the partition of ~(−26) kJ/mol for non-myristoylated peptides, suggesting poor binding to membranes. Myristoylated peptides showed larger Kx values ranging from 1.0 × 105 in POPC to 1.7 × 106 POPC/POPG vesicles, indicating a stronger interaction with LUVs.
Moreover, myristoylated peptides prefer to interact with anionic membranes as described by the values of the selectivity ratio ranging between ~2 and 4. This feature should increase the antifungal activity, as described later. Mc Laughlin and colleagues stated that the presence of the myristoyl moiety is required to interact with membranes but is not always sufficient [38]. The higher propensity of myristoylated peptides to interact with membranes can be explained by the presence of the myristoyl group and charge effects. Mainly, the values of Gibbs free energy ~(−33) kJ/mol are similar to that measured for the insertion of myristate into the bilayer [39]. Thus, the synergism between the myristate insertion into the bilayer and the electrostatic interaction between the lysine residues present in the peptides and the anionic lipids can be the driving force of the process [40].

2.4. Fluorescence Quenching Experiments

Peptides’ topology in the absence and presence of lipid vesicles has been evaluated by monitoring the quenching of Trp-1 by acrylamide. Acrylamide is a small neutral molecule that quenches the tryptophan residue with high efficiency [41]. Quenching experiments were carried out in buffer and lipid vesicles as previously described [42]. Typical results are shown in Figure 3 for myristoylated and non-myristoylated peptides.
In the buffer, all non-myristoylated peptides and myristoylated peptides Myr-A and Myr-C showed typical linear behavior of the fluorescence intensity ratio in the absence (Fo) and in the presence (F) of the quencher vs. the quencher concentration. The same behavior was detected for myristoylated peptides in POPC and POPC/POPG lipid vesicles. The classical Stern–Volmer equation [43]
F o F = 1 + K S V [ Q ]
was used to describe the fluorescence quenching, where KSV is the Stern–Volmer or collisional constant, while Fo and F are the fluorescence in the absence and presence of the acrylamide Q, respectively. Values of KSV are indicative of the dynamic quenching and are higher in buffer solution than in the presence of lipid vesicles (Table 3), suggesting that Trp-1 is less accessible to the quencher in the presence of lipid vesicles and confirming the partition into the lipid bilayer.
As reported in Figure 3, Myr-B in the buffer and non-myristoylated peptides in the presence of lipid vesicles showed non-linear behavior, with downward curvature at high quencher concentrations. This effect can be ascribed to selective quenching [44] due to the presence of two different fluorophore populations (a and b) with a diverse solvent exposition: one more accessible to the quencher and the other less. The fluorescence intensity can be written as:
F o = F o , a   + F o , b
The fraction of total fluorescence has been determined using the following equation [43]:
F o F − F o = 1 f a + 1 f a K a [ Q ]
where fa is the fraction of the accessible fluorophore at an infinite concentration of the quencher and Ka is an average Stern–Volmer constant for the accessible fluorophore both exposed and buried. A plot of, F o F − F o   v s .   1 [ Q ] yields a straight line from which we determined the fitting parameters fa and Ka (Figures S3 and S4). Values of fa for non-myristoylated peptides in the presence of lipid vesicles are between 0.40 and 0.75, indicating two fluorophore populations, one accessible to the quencher and the other deeply buried in the phospholipid bilayer.
Furthermore, we calculated the NAF, defined as the ratio between the Stern–Volmer constant in the presence and absence of LUV [45]:
NAF = ( K S V ) LUV ( K S V ) Buffer
Low values of NAF suggest protection of the fluorophore from the quencher and strong interaction with lipids. NAF values reported in Table 3 are lower for myristoylated peptides than for non-myristoylated, suggesting a better interaction with the lipid vesicles. Peptide Myr-B has a lower value of NAF (0.07), indicating a strong interaction with the lipid and a preference for anionic lipid vesicles. Non-myristoylated peptides show high values of NAF, suggesting a weak interaction with lipid vesicles. All the data agree with the results obtained from the partition studies.

2.5. Circular Dichroism Experiments

Structural transitions of peptides upon the addition of lipid vesicles have been investigated by CD spectroscopy [42]. We explored structural changes of both myristoylated and non-myristoylated peptides upon interaction with anionic and zwitterionic membrane-mimicking systems. In Figure 4, typical titration curves for myristoylated peptides are reported at increasing lipid vesicle concentrations. The explored peptide-to-lipid ratios ranged from 1:0 to 1:40. CD data confirm that all peptides can interact with lipid vesicles of different compositions. Peptides Myr-A and Myr-C show similar CD spectra in buffer (black curves) with a minimum at ~220 nm, typical of a β-conformation. This conformation seems to be stable, and it also persists upon the addition of POPC lipid vesicles. However, there is a slight transition towards a partially helical conformation in the presence of anionic lipid vesicles. The peptide Myr-B shows a typical spectrum of a random coil in buffer and in the presence of lipid vesicles of different compositions.
The fractional helical content fα for the peptides Myr-A and Myr-C in the presence of POPC/POPG lipid vesicles has been estimated using the formula [46]:
f α = θ − θ R C θ H − θ R C  
where θ is the observed ellipticity at 222 nm and θ R C and θ H are the values for a completely random coil and an α-helical conformation, respectively. According to the Luo and Baldwin [47] formula, the limiting values are θ R C = − 360 and θ H = − 39.375 . The helical fractions fα in the presence of POPC/POPG lipid vesicles are ~0.2 and ~0.1 at an L/P molar ratio of 40 for Myr-A and Myr-C, respectively.

2.6. Molecular Dynamics Simulations

To investigate more deeply, with an atomic resolution, the interaction between the peptides and the membrane models, we carried out a series of molecular dynamics simulations of peptides in different environments, including water, TFE/water (50% v/v), and in the presence of POPC and POPC/POPG lipid bilayers.
The initial structure of peptides used for the MD in the solution was obtained using the I-Tasser bioinformatics tool, which suggested, for all peptides, an α-helix conformation.
The MD simulations in water of all peptides showed a rapid loss of the initial α-helix conformation (Figure S5). Only for Myr-B was the formation of a transient α-helix observed during 300 ns of simulation. Analysis of the peptide’s secondary structure as a function of the simulation time suggests that all peptides are unstructured with high conformational flexibility in the water, in agreement with the experimental results obtained by CD spectra.
In the presence of TFE/water (50% v/v), a less polar solvent with respect to water, Pep-B, Pep-C, and Myr-C conserved the α-helix conformation for 300 ns with a helicity of about 45%, 64%, and 82%, respectively (Figure S5). In the case of Pep-A and Myr-A, the analysis of the secondary structure showed an unfolding of peptides after 120 ns and 220 ns of simulation (Figure S5A,B).
We also simulated the adsorption of peptides on the surface of anionic and zwitterionic membrane models. The structures obtained at the end of the MD simulations in TFE/water were used as the initial conformation of peptides for the simulations in the presence of POPC and POPC/POPG lipid bilayers. The peptides were positioned close to the surface of the membranes with the principal axis parallel to the lipid surface and a distance of 1.0 nm between the center of mass of the peptide and the phosphorous atoms of lipids.
Figure 5 shows the representative snapshots of MD simulation at 1 μs of myristoylated peptides in the presence of POPC and POPC/POPG lipid bilayers. Myr-A and Myr-B interact with the surface of the zwitterionic and anionic membrane through an unfolded conformation, while Myr-C shows a higher tendency with respect to the other myristoylated peptide to fold in the presence of lipid bilayers. In particular, analysis of the time evolution of the secondary structure of Myr-C in POPC/POPG shows that the peptide conserves helicity (α-helix and π-helix) of about 45% (five residues) during the simulation duration (Figure S6). On the other hand, in the presence of POPC, Myr-C interacts with the membrane, adopting, in the last 500 ns of simulation, a 310-helix with helicity of about 45.5% (Figure S6).
The adsorption of myristoylated peptides to the surface of the lipid bilayer is driven mainly by the alkyl chain, linked to the N-terminal residue of peptides, and by the presence of positively charged amino acids. The alkyl chain penetrates in the hydrophobic region of the lipid bilayer while the positively charged amino acids stabilize the peptide–membrane interaction by forming hydrogen bonds and electrostatic interactions with lipid molecules. The peptide Myr-A in POPC shows a deep penetration of the myristoyl chain and Trp-1 in the hydrophobic region of the membrane (Figure 5A and Figure S7A). In particular, the average position of Trp-1 is located slightly below the position of the carbonyl group (COsn-1 and COsn-2) of POPC, as evidenced by the analysis of the average density distribution calculated to the lipid bilayer center (Figure S7A). In POPC/POPG (Figure 5B and Figure S7B), the residues of Trp-1 and Lys-4 are located close to the lipid/water surface. The residue Arg-7 interacts with phosphate groups forming an arginine-phosphate salt bridge. The different penetrations into the lipid bilayer of POPC and POPC/POPG observed by MD simulation for Trp-1 of the peptide Myr-A is in agreement with the NAF values obtained by fluorescence-quenching experiments. In POPC/POPG, Trp-1 is close to the lipid surface and then more exposed to the quencher molecules with respect to POPC, where the aromatic residue can penetrate the hydrophobic region of the membrane.
The peptides Myr-B and Myr-C adsorbed on the surface of the lipid membrane show a different orientation with respect to Myr-A. The peptide Myr-B, in the presence of POPC and POPC/POPG, adopts an extended conformation parallel to the lipid surface with charged residues that interact with phosphate groups of lipids, and the residue Trp-1 located in the hydrophobic region of the membrane (Figure 5C,D). Myr-C, which adopts a folding conformation (5–6 residues) when adsorbed by the membrane, in the presence of POPC shows residues of Trp-1 and all lysine residues except Lys-11 located inside the membrane close to the carbonyl group of lipids (Figure 5E and Figure S7E). On the contrary, in POPC/POPG, all charged amino acids of the peptide Myr-C are located close to the phosphate group (Figure 5F and Figure S5F) and interact with lipid molecules via the salt bridge and hydrogen bonds. In the case of Myr-B and Myr-C, analysis of the density distribution calculated with respect to the lipid bilayer center suggests that in POPC/POPG, the residue of Trp-1 is located more inside the membrane with respect to POPC, in agreement with the factor NAF obtained by fluorescence experiments.
The analysis of MD trajectories of non-myristoylated peptides in POPC and POPC/POPG reveals a lower affinity of peptides for lipid bilayers with respect to myristoylated peptides, as shown by the partition constants Kx reported in Table 2. In particular, the peptides Pep-B and Pep-C are adsorbed on the lipid surface and cannot deeply penetrate the membrane but lie on the surface, with the non-charged amino acids oriented toward the water phase (Figures S8 and S9). Figure 6 shows, for example, the different penetrations of Pep-C and Myr-C adsorbed on the lipid surface of POPC/POPG.
The density distribution of Trp-1 atoms, calculated with respect to the lipid bilayer center (Figure S8), shows that for all non-myristoylated peptides, Trp-1 does not penetrate the hydrophobic portion of the membrane but remains located close to phosphate groups of lipids at the lipid/water interface. At the lipid/water interface, the residue Trp-1 is more exposed to water molecules and all molecular species present in the water phase. MD simulation results suggest that Trp-1 of myristoylated peptides is deeply immersed in the hydrophobic region of the membrane and, therefore, poorly exposed to water, with respect to non-myristoylated peptides. These results are in good agreement with the fluorescence experiments.
The MD simulations evidenced that the presence of the myristoyl moiety linked to Pep-A, Pep-B, and Pep-C deeply influences the properties of peptides, particularly their structure and affinity for lipid bilayers.

2.7. Antifungal Activity

The MIC90 values of non-myristoylated and myristoylated peptides against different Candida spp. are summarized in Table 4. All lipopeptides have much lower MIC90 values than their unfunctionalized counterparts, with the sole exception of the Myr-A peptide that maintains an unchanged MIC90 value towards C. auris. As already observed in the literature, these results confirm that increasing hydrophobicity by fatty acylation of AMPs with myristic acid enhances their antimicrobial activity and, in particular, the antifungal properties [48]. The evidenced MIC90 values are between 5 and 21 µM for all selected Candida species, while only Candida auris showed a higher range with Myr-B, which is the most active (MIC90 20 µM). Myr-A and Myr-C were the most active against the selected Candida species, and Myr-B particularly showed a MIC of 8 μg/mL (10 μM) vs. C. tropicalis. Values of the single MICs of the 10 isolates for Candida species are reported in the Supplementary Information (Table S1). MIC values are higher than CMC, so MIC values are determined in the presence of lipopetide micellar aggregates and not the free monomer. Under these conditions, lipopetides are still soluble even if in the form of micellar aggregates. Thus, the activity of lipopetides might also depend on the so-called micellar mechanism, consisting of the solubilization of part of the host membrane into mixed micelles. However, further studies are needed to verify this hypothesis.

2.8. SEM Analysis

The antibiofilm activity of the Myr-B lipopeptide was tested on representative high-biofilm-producing strains of C. albicans, C. tropicalis, and C. auris. These strains were selected for their ability to form biofilms in vitro as assessed by the crystal violet assay (data not shown). SEM images clearly show that Myr-B is able to demolish the biofilm of all three fungal isolates at a concentration of 128 μg/mL (85 μM) (Figure 7). Untreated biofilms show a well-organized three-dimensional structure, with the presence of an extracellular matrix for the C. albicans and C. tropicalis strains and fungal hyphae, well-branched and adhered to the surface. The biofilm of C. auris, as already reported [49], is characterized by cellular aggregates with a poor extracellular matrix able to tolerate clinical concentrations of sodium hypochlorite. After treatment with the Myr-B lipopeptide, the biofilm of all fungal strains is strongly demolished. Few cellular hyphae fragments can be observed, but the morphological organization is completely lost. Biofilm demolition results validate the idea the peptide’s myristoylation strongly enhances the antifungal properties also towards the biofilm form. These results have a significant impact on the search for new peptide drugs able to combat the rising antimicrobial resistance and also effective against biofilm-related infections.

2.9. In Vivo Toxicity and Efficacy Testing in Galleria Mellonella Model

Multidrug-resistant C. auris was chosen as a representative species for in vivo studies. After determining the infective fungal dose of 107 CFU/injection was capable of killing about 50% of the Galleria mellonella larvae 24 h after infection (data not shown), we evaluated the in vivo toxicity and efficacy of the Pep-B and Myr-B peptides (the Myr-B peptide was selected as the best active peptide due to the previously shown results). Groups of ten G. mellonella larvae were infected with C. auris and treated with the Pep-B and Myr-B peptides at a concentration of 640 µg/mL (about 400 µM). The results shown in Table 5 highlighted that the toxicity of Pep-B is slightly higher than that of the corresponding lipopeptide. Furthermore, Myr-B was able to contain the effects of fungal infection 24 h after the treatment, with a single addition of Myr-B: 8 out of 10 larvae survived, whereas, in the control group, only 4 survived. In the group of infected larvae treated with Pep-B, 7 out of 10 larvae died after 24 h, showing poor efficacy compared to the control. In these pilot and preliminary studies with a single drug administration, the data obtained after 24 h are the most significant, as in the following 48 h, the injected compound undergoes inactivation and elimination likely due to the action of internal proteases. Therefore, we could also confirm the antifungal activity of the Myr-B peptide in vivo.

2.10. Cytotoxicity Assay against Human Cell Line

The cytotoxic effect of the six peptides has been investigated on a primary human fibroblast cell line (FB789). Four different peptide concentrations (5, 10, 20, and 50 µM) and two different time points (12 and 24 h) have been tested (see Figure 8). Pep-A, Pep-B, and Pep-C [see panel A–C] and the corresponding Myr-A, Myr-B, and Myr-C [see panel D–F] evidenced no toxicity even at the highest peptide concentration. Moreover, Pep-A, and to a lesser extent Myr-A, showed a proliferative effect. No cytotoxic effect was found in the peptide Myr-B concentrations that were active, both in vitro and in vivo, against the tested fungal species.

2.11. Hemolytic Assay against Rabbit Erythrocytes

Rabbit erythrocytes have been used to investigate the hemolytic effect of the six peptides (Figure 9). Hemolysis values from 5 to 20 µM are rather low, ranging from 0.1% (Peptide-A and Peptide Myr-A at 5 µM, see panel A) to 7% (Peptide Myr-B, see panel B). An increase in the membrane lysis induced by the peptides is visible at 50 µM, with an effect of 28.5% of hemolysis reached by Peptide Myr-C (see panel C). At the concentrations of Myr-B active against Candida species, no or very few hemolytic effects have been evidenced.

3. Conclusions

In recent years, fungal infections have been increasing worldwide, and they are usually associated with relatively high mortality rates. Still, the current antimycotic therapies are limited. Moreover, some Candida species resistant to antibiotics have emerged and new antifungal drugs need to be developed [50]. In this paper, we reported the design and characterization of three lipopeptides active in vitro against different multidrug-resistant Candida species. Lipopeptides were selective and active against fungal cells and not harmful against either fibroblast mammalian cells or erythrocytes. Finally, as the first proof of evidence, we tested the in vivo activity of the most-active peptide, Myr-B, against an infection of Candida auris in insect larvae of Galleria mellonella. The peptide was not toxic and could contain the effects of fungal infection 24 h after the treatment. Therefore, it could be considered a new promising drug candidate. These results could greatly impact the search for new antifungal peptide drugs able to combat the rising antibiotic resistance and against biofilm-related infections.

4. Materials and Methods

4.1. Materials

All the reagents were purchased from Sigma-Merck (Milan, Italy) unless otherwise specified. All peptides and lipo-peptides were purchased from CASLO ApS, c/o Scion Technical University of Denmark, with a purity >98%. Peptide concentrations were determined by UV spectroscopy at 280 nm before each sample preparation.

4.2. Lipid Vesicles Preparation

The lipids POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol) were purchased from Avanti Polar Lipids (Alabaster, AL, USA) and used without further purification. LUVs (Large Unilamellar Vesicles) were prepared as previously reported [37]. Briefly, appropriate amounts of lipids were dissolved in chloroform/methanol 9:1. The solvent was then removed by rotary evaporation and samples were placed overnight under a high vacuum. The lipid film was then hydrated by adding 1 mL of buffer (20 mM phosphate buffer at pH 7.4 with 150 mM NaCl and 0.8 mM EDTA) and then subjected to 5 freeze–thaw cycles and vortexed. The multilamellar vesicles (MLVS) were extruded through a polycarbonate membrane with pores of 100 nm by an Avanti polar mini extruder, and the obtained LUVs were used within 48 h of preparation. LUVs were composed of 100% POPC and a 70%/30% (w/w) combination of POPC/POPG. The final concentration of the lipid was 10 mM.

4.3. Fluorescence Spectroscopy

All the steady-state fluorescence measurements were carried out using a Perkin Elmer LS55 fluorescence spectrophotometer. All the experiments were conducted at 298 K in a thermostatic cell holder and in 20 mM phosphate buffer at pH 7.4 containing 0.8 mM EDTA and 150 mM NaCl unless otherwise specified.

4.3.1. Critical Micellar Concentration (CMC) Determination

The CMC of the N-terminal myristoylated peptides was determined in water by fluorescence spectroscopy using 8-anilinonaphtalene-1-sulfonate (ANS) as the fluorescent probe [51]. The ANS assays were performed using peptide concentrations of 0.8–10.0 μM in 70 μM ANS solution.
The ANS was excited at λex = 356 nm, and the fluorescence spectrum was measured for λem = 400–670 nm with excitation and emission bandwidths of 5 nm.

4.3.2. Partition Constant Determination

Since all peptides contain tryptophan, fluorescence spectroscopy is an appropriate tool for studying these molecules. Peptide partitioning between buffer and lipid vesicles was monitored by measuring the increase in tryptophan fluorescence upon the addition of LUVs. Trp fluorescence spectra were recorded with λexc = 295 nm and scanning the emission between 305 and 400 nm. Measurements were carried out with a cross-oriented configuration of polarizers (polem = 0° and polexc = 90°) [52]. Briefly, a 1.0 μM solution of the peptide was titrated with LUVs of different compositions (POPC 100% and 70%/30% POPC/POPG) as previously described [22,37]. The background effects of vesicles and buffer were subtracted from each spectrum. All the fluorescence emissions were corrected for dilution. Mole fraction partition coefficients Kx were calculated from the fraction of the partitioned peptide fp as previously described [22,37]. The fraction of the partitioned peptide fp is given by the following equation [53]
f p = K x [ L ] [ W ] + K x [ L ]
where Kx is the mole fraction partition constant, and [L] and [W] are the molar concentrations of lipids and water, respectively.

4.3.3. Acrylamide Quenching Experiments

Quenching of tryptophan fluorescence both in the absence and presence of lipid vesicles was accomplished by the addition of small aliquots of acrylamide dissolved in buffer. The concentration was 2.0 μM for both myristoylated and non-myristoylated peptides whereas lipid vesicles were 400 μM in the experiments with myristoylated peptides and 1.0 mM in the experiments with non-myristoylated peptides. The excitation wavelength was set at 295 nm, and fluorescence emission spectra were recorded between 305 and 400 nm. Measured fluorescence was corrected for dilution of the sample, and data were fitted according to the Stern–Volmer or modified Stern–Volmer equation [43].

4.4. Circular Dichroism Spectroscopy

Circular Dichroism (CD) spectra were recorded in the 190–260 nm spectral range at 298 K on a J 715 JASCO spectropolarimeter with 1.0 nm intervals, using a 0.2 cm path-length quartz cuvette. The reported spectra are the average of 8 scans with an instrument scanning speed of 100 nm/min, a step size of 1 nm, and 1s response. Liposomes for CD experiments were prepared as described in Section 4.2 using a 10 mM phosphate buffer (pH 7.4 and 0.1 mM EDTA).
CD spectra of peptides were recorded in 10 mM phosphate buffer (pH 7.4 and 0.1 mM EDTA) in the absence and presence of LUVs of different compositions. The general procedure for non-myristoylated peptides was as follows: To a freshly prepared solution of 30 μM peptide, increasing aliquots of the proper liposome solution were added. After each addition, the solution was left for 5 min to equilibrate under stirring before recording the CD spectrum. The explored lipid/peptide ratios ranged from 1:0 to 1:60.
For myristoylated peptides, six different samples at a 30 μM lipopeptide concentration and increasing liposome concentrations (30 μM, 150 μM, 300 μM, 600 μM, 900 μM, and 1200 μM) were prepared. The samples were allowed to equilibrate for 1 h before recording the CD spectrum.
The CD signals in millidegrees (θ) were converted into mean molar ellipticities (deg cm2 dmol−1) and plotted vs. the wavelength.

4.5. Molecular Dynamics Simulations

4.5.1. Simulation Systems

The initial structure of Pep-A, Pep-B, and Pep-C were obtained using the fold recognition algorithm implemented in I-TASSER (iterative threading assembly refinement algorithm) [54]. Arginine and lysine side chains were considered positively charged according to their protonation state at pH = 7. The structure of myristoylated peptides, Myr-A Myr-B, and Myr-C, were obtained by linking, with an amide bond, the acyl chain to the N-terminal tryptophan residue of Pep-A, Pep-B, and Pep-C using Avogadro software [55].
Four systems were constructed for each peptide. In the first system, the peptide was immersed in a cubic box 5.0 × 5.0 × 5.0 nm3 and solvated with at list 4000 water molecules. In the second system, the peptide was immersed in a cubic box 5.0 × 5.0 × 5.0 nm3 and solvated with a mixture of TFE/water (50% v/v). In the third system, the peptide was positioned close to the surface of the pre-equilibrated bilayer of POPC with the principal axis parallel to the lipid surface and a distance of 1.0 nm between the center of mass of the peptide and the phosphate atoms of lipids. A rectangular box of 6.5 × 6.5 × 9.0 nm3 was used with at least 6500 water molecules. In the fourth system, each peptide was positioned above the pre-equilibrated bilayer surface of POPC/POPG with the principal axis parallel to the lipid surface and a distance of 1.0 nm between the center of mass of the peptide and the phosphate atoms of lipids. A rectangular box of 6.2 × 6.2 × 9.0 nm3 was used with at least 6500 water molecules.
For the simulation in water and the mixture of TFE/water, the best-scored structures of each peptide obtained by the I-TASSER prediction were used. For simulations in the presence of the lipid bilayer of POPC and POPC/POPG, the structure of the peptide obtained at the end of the MD simulation in TFE/water was used to prepare the initial configuration of the system with the peptide close to the surface of the bilayer. The initial configuration of POPC and POPC/POPG (70:30) was built with 128 lipids (64 per leaflet). The mixed bilayer of POPC/POPG (70:30) was built using 92 molecules of POPC and 36 molecules of POPG (18 per leaflet).

4.5.2. Simulation Details

All the molecular dynamics simulations were performed using the GROMACS 2020.3 packages [56]. The GROMOS 54A7 force field [57] was used to model the peptides’ molecules and ions in conjunction with the GROMOS 54A8 containing the new lipid head group parameters proposed by Marzuoli et al. [58] for the lipid molecules of 1-palmitoyl-2-oleoyl-sn-glycero-3-phoshocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-(1-glycerol) (L-POPG), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-D-(1-glycerol) (D-POPG). The phosphatidylglycerol component of the mixed lipid bilayer was a racemic mixture of L-POPG and D-POPG. Water was modelled with the SPC model [59], and the TFE molecules were described using the force field of Fioroni et al. [60].
Van der Waals and electrostatic interactions were calculated using a cut-off of 1.2 nm, and the particle mesh Ewald method (PME) [61] was applied to the long-range electrostatic interactions beyond 1.2 nm. Covalent bonds were constrained using the P-LINCS algorithm [62,63], whereas the geometry of water was constrained with the SETTLE algorithm [64]. Newton’s equation of motion was integrated via the leap-frog algorithm using a time step of 2 fs.
The velocity-rescale thermostat [65] was used to control the temperature of the simulated systems by coupling the peptide, lipids, water, and ions separately to an external bath at 298 K with a coupling constant τ T of 0.1 ps. The pressure was controlled using the Berendsen barostat [66] (P = 1 bar, τp = 1.0 ps). The pressure coupling was isotropic in the case of the simulations in water and in the mixture of TFE/water (50% v/v) and semi-isotropic in the presence of lipid bilayers. Periodic boundary conditions were applied in all three dimensions.
The trajectories obtained by MD simulation were analyzed with the GROMACS analysis tools, VMD 1.9.3 [67], and in-house scripts. Analysis of the secondary structure was performed with the gmx do_dssp tool of GROMACS using the program DSSP [68].

4.6. Antifungal Activity of Peptides

4.6.1. Fungal Strain, Media, and Culture Conditions

The antifungal activity of AMPs was determined against 50 clinical isolates, 10 for each of the following Candida species: C. albicans, C. tropicalis, C. glabrata, C. parapsilosis, and C. auris. The latter were derived from patients with positive blood cultures in four hospitals in India, with known resistance profiles to fluconazole, voriconazole, and echinocandins. Yeast cells were grown in Brain Heart Infusion (BHI) medium (Sigma-Aldrich, Gillingham, UK) for 16 h at 37 °C in a 150-rpm orbital shaker. Cells were then sub-inoculated in a fresh BHI medium and grown to an optical density (OD) of 0.3. The turbidity of the inoculum was adjusted to 0.5 McFarland and diluted 1:500 in RPMI 1640 broth, corresponding to around 2.5 × 105 CFU/mL.

4.6.2. MIC Evaluation

Minimal inhibitory concentrations (MICs) were determined by Broth microdilution susceptibility tests, according to The Clinical and Laboratory Standards Institute (CLSI) international guidelines [69]. A fungal suspension of 0.5 MacFarland was diluted 1:500 in RPMI 1640 broth and incubated in 96 multi-well plates containing AMPs at different concentrations ranging from 0.125 to 256 μg/mL. In this range of concentration, lipopeptides were completely soluble. MIC was defined as the lowest concentration of the peptides at which yeasts showed no visible growth compared to the control. The MIC90 represents the value at which ≥90% of the strains within a test population were inhibited.

4.6.3. Biofilm Conditions and Biofilm Demolition Assays

Fungal strains of C. albicans, C. tropicalis, and C. auris were cultured in BHI and grown at 37 °C overnight, harvested by centrifugation (3000× g, 10 min), resuspended in sterile PBS, and adjusted to a density of 109 colony-forming units (CFU)/mL in RPMI media by measuring the absorbance at 600 nm. A 24-well plate with 13-mm-diameter glass coverslips (Thermanox NUNC, New York, NY, USA) was seeded with 500 mL and grown 3 days at 37 °C for biofilm formation. Once the biofilms were formed, after 3 days incubation, the culture medium was removed, and cells were washed three times with PBS to remove non-adherent cells. The fungal biofilms, highly visible on the disk surface, were then treated with a 200 µL final volume of peptide X in PBS at two different concentrations (128 and 16 µg/mL) for 16 h at 37 °C. The demolition activity was observed in scanning electron microscopy (SEM).

4.6.4. SEM Analysis

Fungal biofilms were analyzed by SEM (Supra 25-Zeiss, Carl Zeiss AG, Oberkochen, Germany). Fixed and dried biofilms were mounted onto an aluminum stab using double-sided carbon tape and coated with a gold/palladium film (80:20) using a high-resolution sputter coater (SCD-040, Balzers Union Ltd., Balzers, Lichtenstein).

4.6.5. Galleria Mellonella Model

Ten larvae (250–320 mg each) were selected at random for each step in the procedure. Any larvae with darkening of the cuticle were discarded. The test compounds and yeast were injected into the hemocoel in water buffer through the last left proleg (Insumed 30G Pic, Italy, syringe volume 0.5 mL, needle size 30G) [70]. The larvae were incubated in the dark for 3 days, and mortality was recorded daily.
An infective dose of yeast Candida auris was determined by injecting groups of ten larvae with a suspension at 105, 106, 107, and 108 colony-forming units (CFU) per injection. The larvae were incubated for 3 days at 30 °C. An infective dose was defined as the one that caused an immune response, recognizable by the darkening of the cuticle and able to kill approximately 50% of larvae after 24 h [70].
For the peptide efficacy experiment, ten larvae were injected into the last left proleg with a pre-determined infective dose of yeast and the dose of peptides at the same time in a final volume of 10 μL and incubated at 30 °C. Each step in the procedure included six groups of 10 larvae: C. auris-infected larvae (107 CFU), infected and treated larvae with peptide B (640 μg/mL), infected and treated larvae with peptide Myr-B (640 μg/mL), treated larvae with peptide B (640 μg/mL), treated larvae with peptide Myr-B (640 μg/mL), and vehicle-injected control (water). The mortality was recorded daily for 3 days.

4.7. Cytotoxicity Assay against Human Cell Line

The cytotoxicity of the six peptides was tested on a primary human fibroblast cell line (FB789) grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal calf serum (FCS) and antibiotics (penicillin–streptomycin, Gibco) at 37 °C in a humidified 5% CO2 atmosphere. Cells were seeded on 96-well microplates at a density of 3 × 103 cells per well in 100 µL of the medium. Four dilutions of the six peptides (from 5 µM to 50 µM) were added to the cells and maintained for 12 and 24 h. As a negative control, cells were grown in a normal medium without the peptides, while, as a positive control, cells were added to NaN3 10% v/v. The cytotoxicity was determined by measuring the intracellular adenosine triphosphate (ATP) levels using the luciferase-based ATPlite assay (PerkinElmer, Waltham, MA, USA), according to the manufacturer’s instructions. After 12 and 24 h, the cells were lysed, and the lysates were transferred into opaque well plates (OptiPlate-96, PerkinElmer). The amount of emitted light, linearly correlated with the ATP concentration, was measured with a microplate luminometer (Victor II PerkinElmer) for 10 min in the dark. Three replicates for each dilution were performed. Cell viability values were expressed as the mean + SD and calculated as the percent values of the treated samples with respect to the untreated cells (negative control). The statistical analysis was performed using one-way ANOVA analysis followed by the Dunnett post-test.

4.8. Hemolytic Activity Assay

The hemolytic assay was performed on rabbit erythrocytes (Rockland) maintained in Alsever’s solution (Innovative Research). Briefly, after the removal of Alsever’s solution, the erythrocytes were resuspended in PBS and counted in a hemocytometer. A suspension of 5,000,000 red blood cells was incubated with four dilutions (from 5 µm to 50 µm) of the six peptides in a 96-well microplate. As a negative control, erythrocytes were incubated without the peptides, while as a positive control, erythrocyte was added with triton 10% v/v. The plate was incubated at 37 °C for 2 h and subsequently centrifuged at 1200 rpm × 3 min to separate the pellet from the supernatant. The absorbance of the supernatant was measured at 492 nm. Each point was made in triplicate. The relative OD compared to the positive control defined the percentage of hemolysis [71]. Statistical analysis was performed using two-way ANOVA analysis followed by Bonferroni’s post-test.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms23042164/s1.

Author Contributions

F.B. (Francesca Bugli) and F.M. equally contributed. Conceptualization, F.P., F.B. (Francesca Bugli) and F.B. (Francesco Buonocore); methodology, F.M., F.P., F.C., C.B. and S.B.; software, S.B.; validation, F.M., C.B. and F.C.; formal analysis, S.B. and C.B.; investigation, F.M., R.T., M.M., M.D.V., R.M., P.R.S. and M.S.; resources, F.P., M.S., F.B., C.B. and F.B.; data curation, F.M., F.C., R.T., M.M., M.D.V., R.M., P.R.S. and M.S.; writing—original draft preparation, F.P., F.B. (Francesca Bugli), S.B. and F.B. (Francesco Buonocore); writing—review and editing, F.P., S.B., F.B. (Francesca Bugli) and F.B. (Francesco Buonocore); visualization, F.P., F.B. (Francesca Bugli) and F.B. (Francesco Buonocore); supervision, F.B. (Francesca Bugli), F.P., F.B. (Francesco Buonocore) and M.S.; funding acquisition, F.B. (Francesca Bugli), F.P., F.B. (Francesco Buonocore) and M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was partially funded by Regione Lazio, grant number A0375-2020-36557, in the call “Gruppi di Ricerca 2020”. Name of the project: “New Antimicrobial Peptides delivered in specific nanosystems against ESKAPE bacteria: a weapon against antibiotic resistance (NanopeptoBat)”.

Institutional Review Board Statement

Not Applicable.

Informed Consent Statement

Not Applicable.

Data Availability Statement

The data are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

AMPAntimicrobial peptide
ANS8-anilinonaphtalene-1-sulfonate
CDCircular dichroism
CMCCritical micellar concentration
EDTAEthylenediaminetetraacetic acid
FDAFood and drug administration
LUVLarge unilamellar vesicles
MDMolecular dynamics
MICMinimum inhibitory concentration
MLVSMultilamellar vesicles
NAF Net accessibility factor
POPC1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
POPG1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
SEMScanning electron microscope
TFEtrifluoroethanol

References

  1. Brown, G.D.; Denning, D.W.; Gow, N.A.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 165rv113. [Google Scholar] [CrossRef] [PubMed]
  2. Wiederhold, N.P. The antifungal arsenal: Alternative drugs and future targets. Int. J. Antimicrob. Agents 2018, 51, 333–339. [Google Scholar] [CrossRef] [PubMed]
  3. Revie, N.M.; Iyer, K.R.; Robbins, N.; Cowen, L.E. Antifungal drug resistance: Evolution, mechanisms and impact. Curr. Opin. Microbiol. 2018, 45, 70–76. [Google Scholar] [CrossRef] [PubMed]
  4. Lai, Y.; Gallo, R.L. AMPed up immunity: How antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009, 30, 131–141. [Google Scholar] [CrossRef] [PubMed]
  5. Landy, M.; Warren, G.H.; RosenmanM, S.B.; Colio, L.G. Bacillomycin: An antibiotic from Bacillus subtilis active against pathogenic fungi. Proc. Soc. Exp. Biol. Med. 1948, 67, 539–541. [Google Scholar] [CrossRef]
  6. Faruck, M.O.; Yusof, F.; Chowdhury, S. An overview of antifungal peptides derived from insect. Peptides 2016, 80, 80–88. [Google Scholar] [CrossRef] [PubMed]
  7. De Cesare, G.B.; Cristy, S.A.; Garsin, D.A.; Lorenz, M.C. Antimicrobial Peptides: A New Frontier in Antifungal Therapy. mBio 2020, 11, e02123-20. [Google Scholar] [CrossRef]
  8. Jiang, Z.; Vasil, A.I.; Gera, L.; Vasil, M.L.; Hodges, R.S. Rational design of alpha-helical antimicrobial peptides to target Gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: Utilization of charge, ‘specificity determinants,’ total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem. Biol. Drug Des. 2011, 77, 225–240. [Google Scholar] [CrossRef]
  9. Rautenbach, M.; Troskie, A.M.; Vosloo, J.A. Antifungal peptides: To be or not to be membrane active. Biochimie 2016, 130, 132–145. [Google Scholar] [CrossRef]
  10. Cools, T.L.; Vriens, K.; Struyfs, C.; Verbandt, S.; Ramada, M.H.S.; Brand, G.D.; Bloch, C., Jr.; Koch, B.; Traven, A.; Drijfhout, J.W.; et al. The Antifungal Plant Defensin HsAFP1 Is a Phosphatidic Acid-Interacting Peptide Inducing Membrane Permeabilization. Front. Microbiol. 2017, 8, 2295. [Google Scholar] [CrossRef]
  11. Pouny, Y.; Rapaport, D.; Mor, A.; Nicolas, P.; Shai, Y. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 1992, 31, 12416–12423. [Google Scholar] [CrossRef] [PubMed]
  12. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005, 3, 238–250. [Google Scholar] [CrossRef] [PubMed]
  13. Zhao, P.; Xue, Y.; Gao, W.; Li, J.; Zu, X.; Fu, D.; Feng, S.; Bai, X.; Zuo, Y.; Li, P. Actinobacteria-Derived peptide antibiotics since 2000. Peptides 2018, 103, 48–59. [Google Scholar] [CrossRef] [PubMed]
  14. El Shazely, B.; Yu, G.; Johnston, P.R.; Rolff, J. Resistance Evolution Against Antimicrobial Peptides in Staphylococcus aureus Alters Pharmacodynamics Beyond the MIC. Front. Microbiol. 2020, 11, 103. [Google Scholar] [CrossRef]
  15. Yu, G.; Baeder, D.Y.; Regoes, R.R.; Rolff, J. Predicting drug resistance evolution: Insights from antimicrobial peptides and antibiotics. Proc. Biol. Sci. 2018, 285, 20172687. [Google Scholar] [CrossRef]
  16. Oshiro, K.G.N.; Rodrigues, G.; Monges, B.E.D.; Cardoso, M.H.; Franco, O.L. Bioactive Peptides Against Fungal Biofilms. Front. Microbiol. 2019, 10, 2169. [Google Scholar] [CrossRef]
  17. Eisenstein, B.I. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin. Investig. Drugs 2004, 13, 1159–1169. [Google Scholar] [CrossRef]
  18. Gong, H.; Sani, M.A.; Hu, X.; Fa, K.; Hart, J.W.; Liao, M.; Hollowell, P.; Carter, J.; Clifton, L.A.; Campana, M.; et al. How do Self-Assembling Antimicrobial Lipopeptides Kill Bacteria? ACS Appl. Mater. Interfaces 2020, 12, 55675–55687. [Google Scholar] [CrossRef]
  19. Aisenbrey, C.; Marquette, A.; Bechinger, B. The Mechanisms of Action of Cationic Antimicrobial Peptides Refined by Novel Concepts from Biophysical Investigations. Adv. Exp. Med. Biol. 2019, 1117, 33–64. [Google Scholar] [CrossRef]
  20. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. USA 2006, 103, 15997–16002. [Google Scholar] [CrossRef]
  21. Malina, A.; Shai, Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem. J. 2005, 390, 695–702. [Google Scholar] [CrossRef] [PubMed]
  22. Olivieri, C.; Bugli, F.; Menchinelli, G.; Veglia, G.; Buonocore, F.; Scapigliati, G.; Stocchi, V.; Ceccacci, F.; Papi, M.; Sanguinetti, M.; et al. Design and characterization of chionodracine-derived antimicrobial peptides with enhanced activity against drug-resistant human pathogens. RSC Adv. 2018, 8, 41331–41346. [Google Scholar] [CrossRef]
  23. Hancock, R.E.; Rozek, A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol. Lett. 2002, 206, 143–149. [Google Scholar] [CrossRef] [PubMed]
  24. Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1999, 1462, 55–70. [Google Scholar] [CrossRef]
  25. Matsuzaki, K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1999, 1462, 1–10. [Google Scholar] [CrossRef]
  26. Wimley, W.C. Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem. Biol. 2010, 5, 905–917. [Google Scholar] [CrossRef] [PubMed]
  27. Gong, H.; Zhang, J.; Hu, X.; Li, Z.; Fa, K.; Liu, H.; Waigh, T.A.; McBain, A.; Lu, J.R. Hydrophobic Control of the Bioactivity and Cytotoxicity of de Novo-Designed Antimicrobial Peptides. ACS Appl. Mater. Interfaces 2019, 11, 34609–34620. [Google Scholar] [CrossRef]
  28. Ong, Z.Y.; Cheng, J.; Huang, Y.; Xu, K.; Ji, Z.; Fan, W.; Yang, Y.Y. Effect of stereochemistry, chain length and sequence pattern on antimicrobial properties of short synthetic beta-sheet forming peptide amphiphiles. Biomaterials 2014, 35, 1315–1325. [Google Scholar] [CrossRef]
  29. Domhan, C.; Uhl, P.; Meinhardt, A.; Zimmermann, S.; Kleist, C.; Lindner, T.; Leotta, K.; Mier, W.; Wink, M. A novel tool against multiresistant bacterial pathogens: Lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. Int. J. Antimicrob. Agents 2018, 52, 52–62. [Google Scholar] [CrossRef]
  30. Wenzel, M.; Schriek, P.; Prochnow, P.; Albada, H.B.; Metzler-Nolte, N.; Bandow, J.E. Influence of lipidation on the mode of action of a small RW-rich antimicrobial peptide. Biochim. Biophys. Acta 2016, 1858, 1004–1011. [Google Scholar] [CrossRef]
  31. Liu, L.; Xu, K.; Wang, H.; Tan, P.K.; Fan, W.; Venkatraman, S.S.; Li, L.; Yang, Y.Y. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 2009, 4, 457–463. [Google Scholar] [CrossRef]
  32. Schnaider, L.; Brahmachari, S.; Schmidt, N.W.; Mensa, B.; Shaham-Niv, S.; Bychenko, D.; Adler-Abramovich, L.; Shimon, L.J.W.; Kolusheva, S.; DeGrado, W.F.; et al. Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity. Nat. Commun. 2017, 8, 1365. [Google Scholar] [CrossRef]
  33. Hawe, A.; Sutter, M.; Jiskoot, W. Extrinsic fluorescent dyes as tools for protein characterization. Pharm. Res. 2008, 25, 1487–1499. [Google Scholar] [CrossRef] [PubMed]
  34. Reid, K.A.; Davis, C.M.; Dyer, R.B.; Kindt, J.T. Binding, folding and insertion of a beta-hairpin peptide at a lipid bilayer surface: Influence of electrostatics and lipid tail packing. Biochim. Biophys. Acta Biomembr. 2018, 1860, 792–800. [Google Scholar] [CrossRef] [PubMed]
  35. Scheidt, H.A.; Sickert, A.; Meier, T.; Castellucci, N.; Tomasini, C.; Huster, D. The interaction of lipid modified pseudopeptides with lipid membranes. Org. Biomol. Chem. 2011, 9, 6998–7006. [Google Scholar] [CrossRef] [PubMed]
  36. Dathe, M.; Nikolenko, H.; Meyer, J.; Beyermann, M.; Bienert, M. Optimization of the antimicrobial activity of magainin peptides by modification of charge. FEBS Lett. 2001, 501, 146–150. [Google Scholar] [CrossRef]
  37. Olivieri, C.; Buonocore, F.; Picchietti, S.; Taddei, A.R.; Bernini, C.; Scapigliati, G.; Dicke, A.A.; Vostrikov, V.V.; Veglia, G.; Porcelli, F. Structure and membrane interactions of chionodracine, a piscidin-like antimicrobial peptide from the icefish Chionodraco hamatus. Biochim. Biophys. Acta 2015, 1848, 1285–1293. [Google Scholar] [CrossRef]
  38. Murray, D.; Ben-Tal, N.; Honig, B.; McLaughlin, S. Electrostatic interaction of myristoylated proteins with membranes: Simple physics, complicated biology. Structure 1997, 5, 985–989. [Google Scholar] [CrossRef]
  39. Buser, C.A.; Sigal, C.T.; Resh, M.D.; McLaughlin, S. Membrane binding of myristylated peptides corresponding to the NH2 terminus of Src. Biochemistry 1994, 33, 13093–13101. [Google Scholar] [CrossRef]
  40. Murray, D.; Hermida-Matsumoto, L.; Buser, C.A.; Tsang, J.; Sigal, C.T.; Ben-Tal, N.; Honig, B.; Resh, M.D.; McLaughlin, S. Electrostatics and the Membrane Association of Src: Theory and Experiment. Biochemistry 1998, 37, 2145–2159. [Google Scholar] [CrossRef] [PubMed]
  41. Phillips, S.R.; Wilson, L.J.; Borkman, R.F. Acrylamide and iodide fluorescence quenching as a structural probe of tryptophan microenvironment in bovine lens crystallins. Curr. Eye Res. 1986, 5, 611–619. [Google Scholar] [CrossRef] [PubMed]
  42. Della Pelle, G.; Pera, G.; Belardinelli, M.C.; Gerdol, M.; Felli, M.; Crognale, S.; Scapigliati, G.; Ceccacci, F.; Buonocore, F.; Porcelli, F. Trematocine, a Novel Antimicrobial Peptide from the Antarctic Fish Trematomus bernacchii: Identification and Biological Activity. Antibiotics 2020, 9, 66. [Google Scholar] [CrossRef] [PubMed]
  43. Lackowicz, J.R. Principle of Fluorescence Spectroscopy; Springer: Boston, MA, USA, 2006. [Google Scholar]
  44. Eftink, M.R.; Ghiron, C.A. Exposure of tryptophanyl residues in proteins. Quantitative determination by fluorescence quenching studies. Biochemistry 1976, 15, 672–680. [Google Scholar] [CrossRef] [PubMed]
  45. Saikia, K.; Chaudhary, N. Interaction of MreB-derived antimicrobial peptides with membranes. Biochem. Biophys. Res. Commun. 2018, 498, 58–63. [Google Scholar] [CrossRef]
  46. Fernández-Vidal, M.; White, S.H.; Ladokhin, A.S. Membrane partitioning: “Classical” and “nonclassical” hydrophobic effects. J. Membr. Biol. 2011, 239, 5–14. [Google Scholar] [CrossRef]
  47. Luo, P.; Baldwin, R.L. Mechanism of helix induction by trifluoroethanol: A framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water. Biochemistry 1997, 36, 8413–8421. [Google Scholar] [CrossRef]
  48. Sharma, H.; Mathew, B.; Nagaraj, R. Engineering of a linear inactive analog of human beta-defensin 4 to generate peptides with potent antimicrobial activity. J. Pept. Sci. 2015, 21, 501–511. [Google Scholar] [CrossRef]
  49. Short, B.; Brown, J.; Delaney, C.; Sherry, L.; Williams, C.; Ramage, G.; Kean, R. Candida auris exhibits resilient biofilm characteristics in vitro: Implications for environmental persistence. J. Hosp. Infect. 2019, 103, 92–96. [Google Scholar] [CrossRef]
  50. Murphy, S.E.; Bicanic, T. Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. Front. Cell. Infect. Microbiol. 2021, 11, 759408. [Google Scholar] [CrossRef]
  51. Hutchinson, J.A.; Hamley, I.W.; Torras, J.; Aleman, C.; Seitsonen, J.; Ruokolainen, J. Self-Assembly of Lipopeptides Containing Short Peptide Fragments Derived from the Gastrointestinal Hormone PYY3-36: From Micelles to Amyloid Fibrils. J. Phys. Chem. B 2019, 123, 614–621. [Google Scholar] [CrossRef]
  52. Ladokhin, A.S.; Jayasinghe, S.; White, S.H. How to measure and analyze tryptophan fluorescence in membranes properly, and why bother? Anal. Biochem. 2000, 285, 235–245. [Google Scholar] [CrossRef] [PubMed]
  53. Ladokhin, A.S. Fluorescence spectroscopy in thermodynamic and kinetic analysis of pH-dependent membrane protein insertion. Meth. Enzymol. 2009, 466, 19–42. [Google Scholar]
  54. Zhang, Y. I-TASSER server for protein 3D structure prediction. BMC Bioinform. 2008, 9, 40. [Google Scholar] [CrossRef] [PubMed]
  55. Hanwell, M.D.; Curtis, D.E.; Lonie, D.C.; Vandermeersch, T.; Zurek, E.; Hutchison, G.R. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminform. 2012, 4, 17. [Google Scholar] [CrossRef] [PubMed]
  56. Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindahl, E. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015, 1–2, 19–25. [Google Scholar] [CrossRef]
  57. Schmid, N.; Eichenberger, A.P.; Choutko, A.; Riniker, S.; Winger, M.; Mark, A.E.; van Gunsteren, W.F. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J. 2011, 40, 843–856. [Google Scholar] [CrossRef]
  58. Marzuoli, I.; Margreitter, C.; Fraternali, F. Lipid Head Group Parameterization for GROMOS 54A8: A Consistent Approach with Protein Force Field Description. J. Chem. Theory Comput. 2019, 15, 5175–5193. [Google Scholar] [CrossRef]
  59. Berendsen, H.J.C.; Postma, J.P.M.; van Gunsteren, W.F.; Hermans, J. Interaction Models for Water in Relation to Protein Hydration. In Intermolecular Forces; Reidel Publishing Company: Dordrecht, The Netherlands, 1981; pp. 331–342. [Google Scholar]
  60. Fioroni, M.; Burger, K.; Mark, A.E.; Roccatano, D. A new 2,2,2-Trifluoroethanol model for molecular dynamics simulations. J. Phys. Chem. B 2000, 104, 12347–12354. [Google Scholar] [CrossRef]
  61. Darden, T.; York, D.; Pedersen, L. Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems. J. Chem. Phys. 1993, 98, 10089–10092. [Google Scholar] [CrossRef]
  62. Hess, B.; Bekker, H.; Berendsen, H.J.C.; Fraaije, J.G.E.M. LINCS: A linear constraint solver for molecular simulations. J. Comp. Chem. 1997, 18, 1463–1472. [Google Scholar] [CrossRef]
  63. Hess, B. P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation. J. Chem. Theory Comput. 2007, 4, 116–122. [Google Scholar] [CrossRef] [PubMed]
  64. Miyamoto, S.; Kollman, P.A. SETTLE: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comp. Chem. 1992, 13, 952–962. [Google Scholar] [CrossRef]
  65. Bussi, G.; Donadio, D.; Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 2007, 126, 14101–14107. [Google Scholar] [CrossRef] [PubMed]
  66. Berendsen, H.J.C.; Postma, J.P.M.; van Gunsteren, W.F.; Di Nola, A.; Haak, J.R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684–3690. [Google Scholar] [CrossRef]
  67. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33–38. [Google Scholar] [CrossRef]
  68. Kabsch, W.; Sander, C. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983, 22, 2577–2637. [Google Scholar] [CrossRef]
  69. CLSI Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; CLSI Supplement M27-S4; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2012. [Google Scholar]
  70. Harding, C.R.; Schroeder, G.N.; Collins, J.W.; Frankel, G. Use of Galleria mellonella as a model organism to study Legionella pneumophila infection. J. Vis. Exp. 2013, 81, e50964. [Google Scholar] [CrossRef]
  71. Belokoneva, O.S.; Villegas, E.; Corzo, G.; Dai, L.; Nakajima, T. The hemolytic activity of six arachnid cationic peptides is affected by the phosphatidylcholine-to-sphingomyelin ratio in lipid bilayers. Biochim. Biophys. Acta 2003, 1617, 22–30. [Google Scholar] [CrossRef]
Ijms 23 02164 g001 550
Figure 1. Determination of CMC. (A) ANS fluorescence spectra of peptide Myr-C at increasing concentration. (B) The plot of ANS fluorescence at 465 nm vs. logarithm of lipopeptide concentration. The intersection of the lines indicates the CMC.
Figure 1. Determination of CMC. (A) ANS fluorescence spectra of peptide Myr-C at increasing concentration. (B) The plot of ANS fluorescence at 465 nm vs. logarithm of lipopeptide concentration. The intersection of the lines indicates the CMC.
Ijms 23 02164 g001
Ijms 23 02164 g002 550
Figure 2. Partition isotherms for myristoylated (left column) and non-myristoylated peptides (right column) in the presence of zwitterionic and anionic LUVs. The peptide concentration was 1.0 μM. The experiments were performed in quadruplicate, and representative results are shown.
Figure 2. Partition isotherms for myristoylated (left column) and non-myristoylated peptides (right column) in the presence of zwitterionic and anionic LUVs. The peptide concentration was 1.0 μM. The experiments were performed in quadruplicate, and representative results are shown.
Ijms 23 02164 g002
Ijms 23 02164 g003 550
Figure 3. Stern–Volmer plots for the quenching of Trp-1 by acrylamide. Top plots represent myristoylated peptides, whereas bottom plots show non-myristoylated peptides.
Figure 3. Stern–Volmer plots for the quenching of Trp-1 by acrylamide. Top plots represent myristoylated peptides, whereas bottom plots show non-myristoylated peptides.
Ijms 23 02164 g003
Ijms 23 02164 g004 550
Figure 4. CD-spectra of myristoylated peptides in phosphate buffer (black) and in the presence of increasing amounts of lipid vesicles: (A) Myr-A with POPC vesicles, (D) Myr-A with POPC/POPG vesicles, (B) Myr-B with POPC vesicles, (E) Myr-B with POPC/POPG vesicles, (C) Myr-C with POPC vesicles, (F) Myr-C with POPC/POPG vesicles. The peptide-to-lipid ratio R ranges from 0 to 40.
Figure 4. CD-spectra of myristoylated peptides in phosphate buffer (black) and in the presence of increasing amounts of lipid vesicles: (A) Myr-A with POPC vesicles, (D) Myr-A with POPC/POPG vesicles, (B) Myr-B with POPC vesicles, (E) Myr-B with POPC/POPG vesicles, (C) Myr-C with POPC vesicles, (F) Myr-C with POPC/POPG vesicles. The peptide-to-lipid ratio R ranges from 0 to 40.
Ijms 23 02164 g004
Ijms 23 02164 g005 550
Figure 5. Snapshot of MD simulation at 1 μs of (A) Myr-A in POPC, (B) Myr-A in POPC/POPG, (C) Myr-B in POPC, (D) Myr-B in POPC/POPG, (E) Myr-C in POPC, and (F) Myr-C in POPC/POPG. The phosphorous atoms of lipids are represented as orange dots. The residues of lysine, arginine, tryptophan, and myristoyl chain are represented as sticks, whereas the hydrophobic amino acids are represented as orange sticks. The water and counterions are omitted for clarity.
Figure 5. Snapshot of MD simulation at 1 μs of (A) Myr-A in POPC, (B) Myr-A in POPC/POPG, (C) Myr-B in POPC, (D) Myr-B in POPC/POPG, (E) Myr-C in POPC, and (F) Myr-C in POPC/POPG. The phosphorous atoms of lipids are represented as orange dots. The residues of lysine, arginine, tryptophan, and myristoyl chain are represented as sticks, whereas the hydrophobic amino acids are represented as orange sticks. The water and counterions are omitted for clarity.
Ijms 23 02164 g005
Ijms 23 02164 g006 550
Figure 6. Snapshot of MD simulations of Pep-C (A) and Myr-C (B) in POPC/POPG. The secondary structure of peptides is represented in cartoon and α-helix is colored in red, while lysine, tryptophan, and myristoyl chains are represented as sticks. The lipid molecules are represented as thin sticks and colored according to their atom types (red for oxygen, blue for nitrogen, orange for phosphorous atoms, grey for carbon atoms of POPC and POPG). Phosphorous atoms of lipid molecules are represented as orange spheres. The water and counterions are omitted for clarity.
Figure 6. Snapshot of MD simulations of Pep-C (A) and Myr-C (B) in POPC/POPG. The secondary structure of peptides is represented in cartoon and α-helix is colored in red, while lysine, tryptophan, and myristoyl chains are represented as sticks. The lipid molecules are represented as thin sticks and colored according to their atom types (red for oxygen, blue for nitrogen, orange for phosphorous atoms, grey for carbon atoms of POPC and POPG). Phosphorous atoms of lipid molecules are represented as orange spheres. The water and counterions are omitted for clarity.
Ijms 23 02164 g006
Ijms 23 02164 g007 550
Figure 7. SEM images showing the details of treated and untreated Candida biofilms. (A1,A2) Untreated C. albicans biofilm (magnification 500× and 1800×, respectively); (A3,A4) treated C. albicans biofilm (magnification 500× and 1800×, respectively) with peptide Myr-B 128 µg/mL. (B1,B2) untreated C. tropicalis biofilm; (B3,B4) treated C. tropicalis biofilm with peptide Myr-B128 µg/mL. (C1,C2) untreated C. auris biofilm; (C3,C4) treated C. auris biofilm with peptide Myr-B 128 µg/mL (85 µM).
Figure 7. SEM images showing the details of treated and untreated Candida biofilms. (A1,A2) Untreated C. albicans biofilm (magnification 500× and 1800×, respectively); (A3,A4) treated C. albicans biofilm (magnification 500× and 1800×, respectively) with peptide Myr-B 128 µg/mL. (B1,B2) untreated C. tropicalis biofilm; (B3,B4) treated C. tropicalis biofilm with peptide Myr-B128 µg/mL. (C1,C2) untreated C. auris biofilm; (C3,C4) treated C. auris biofilm with peptide Myr-B 128 µg/mL (85 µM).
Ijms 23 02164 g007
Ijms 23 02164 g008 550
Figure 8. Cytotoxic activity of the six peptides against a primary human fibroblast cell line (FB789). (A–C) Non myristoylated peptides; (D–F) Myristoylated peptides. Four different concentrations and two time points have been tested. The values represent the mean + SD (n = 3). The asterisks indicate the significance level with respect to negative control (0% of toxicity): *** = p < 0.001; ** = p < 0.005; * = p < 0.05.
Figure 8. Cytotoxic activity of the six peptides against a primary human fibroblast cell line (FB789). (A–C) Non myristoylated peptides; (D–F) Myristoylated peptides. Four different concentrations and two time points have been tested. The values represent the mean + SD (n = 3). The asterisks indicate the significance level with respect to negative control (0% of toxicity): *** = p < 0.001; ** = p < 0.005; * = p < 0.05.
Ijms 23 02164 g008
Ijms 23 02164 g009 550
Figure 9. Hemolytic activity of the six peptides against rabbit erythrocytes (A) Pep-A and Myr-A; (B) Pep-B and Myr-B; (C) Pep-C and Myr-C. Four different concentrations have been tested. The values represent the mean + SD (n = 3). The asterisks indicate the significance level with respect to positive control (100% of hemolysis): ***= p < 0.001.
Figure 9. Hemolytic activity of the six peptides against rabbit erythrocytes (A) Pep-A and Myr-A; (B) Pep-B and Myr-B; (C) Pep-C and Myr-C. Four different concentrations have been tested. The values represent the mean + SD (n = 3). The asterisks indicate the significance level with respect to positive control (100% of hemolysis): ***= p < 0.001.
Ijms 23 02164 g009
Table
Table 1. Physico-chemical properties of peptides and lipopeptides from the Chionodracine mutant KHS-Cnd.
Table 1. Physico-chemical properties of peptides and lipopeptides from the Chionodracine mutant KHS-Cnd.
Peptide NameSequenceNet Charge at Neutral pHMolecular Weight (Da)
KHS-CndWFGKLYRGITKVVKKVKGLLKG72519.16
Pep-AWFGKLYRGITK31368.66
Pep-BWRGITKVVKKV41313.66
Pep-CWVVKKVKGLLK41297.71
Myr-AMyr-WFGKLYRGITK21579.04
Myr-BMyr-WRGITKVVKKV31524.04
Myr-CMyr-WVVKKVKGLLK31508.09
Table
Table 2. Partition parameters in the presence of LUVs of different compositions.
Table 2. Partition parameters in the presence of LUVs of different compositions.
PeptideLipid CompositionKXΔG (kJ/mol)Selectivity Ratio
Myr-APOPC(1.03 ± 0.04) × 105−28.584.17
POPC/POPG(4.3 ± 0.8) × 105−32.15
Myr-BPOPC(4.7 ± 0.6) × 105−32.373.62
POPC/POPG(1.7 ± 0.2) × 106−35.56
Myr-CPOPC(4.9 ± 0.3) × 105−32.442.45
POPC/POPG(1.2 ± 0.2) × 106−34.70
Pep-APOPC(3.0 ± 0.1) × 104−25.551.73
POPC/POPG(5.2 ± 0.4) × 104−26.92
Pep-BPOPC(4.2 ± 0.2) × 104−26.390.91
POPC/POPG(3.8 ± 0.6) × 104−26.14
Pep-CPOPC(4.4 ± 0.2) × 104−26.500.30
POPC/POPG(1.3 ± 0.2) × 104−23.48
Table
Table 3. Stern–Volmer constant (Ksv and Ka), fraction accessible to the quencher (fa), and Net Accessibility Factor (NAF) for myristoylated peptides in the presence/absence of vesicles of different compositions. NAF and fa are defined in the text.
Table 3. Stern–Volmer constant (Ksv and Ka), fraction accessible to the quencher (fa), and Net Accessibility Factor (NAF) for myristoylated peptides in the presence/absence of vesicles of different compositions. NAF and fa are defined in the text.
PeptideLUV CompositionKSV (M−1)faKa (M−1)NAF
Myr-ABuffer8.0 ± 0.11
POPC2.1 ± 0.21 0.26
POPC/POPG2.9 ± 0.11 0.36
Myr-BBuffer 0.9234.7 ± 0.6
POPC5.1 ± 0.110.15
POPC/POPG2.3 ± 0.110.07
Myr-CBuffer20.5 ± 11
POPC4.4 ± 0.11 0.21
POPC/POPG2.7 ± 0.11 0.13
Pep-ABuffer23.7 ± 0.41
POPC0.5014.3 ± 0.10.60
POPC/POPG0.5514.5 ± 0.20.61
Pep-BBuffer21 ± 0.11
POPC0.3621 ± 0.21.00
POPC/POPG0.4417.0 ± 0.10.81
Pep-CBuffer38.8 ± 0.61
POPC0.4435 ± 0.10.90
POPC/POPG0.7221 ± 0.10.54
Table
Table 4. MIC90 values of peptides and lipopetides in μg/mL against different Candida spp.
Table 4. MIC90 values of peptides and lipopetides in μg/mL against different Candida spp.
MIC μg/mL (Range)
Candida spp.Pep-AMyr-APep-BMyr-BPep-CMyr-C
C. albicans>25616 (8–16)>25616>25632
C. glabrata>25616>25632 (16–32)>25632
C. parapsilosis>25616>25632>25632
C. tropicalis>25616>2568>25616
C. auris>256>256>25616 (16–32)>25664 (16–64)
Table
Table 5. In vivo toxicity data.
Table 5. In vivo toxicity data.
DAY 1DAY 2DAY 3
StrainPeptideDeadAliveDeadAliveDeadAlive
Peptide toxicity-Pep-B375591
-Myr-B191919
Peptide efficacyCandida aurisPep-B73100100
Myr-B287373
Control *Candida auris-647373
Note. * The control group larvae were infected with the pathogen but not treated with peptides.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Bugli, F.; Massaro, F.; Buonocore, F.; Saraceni, P.R.; Borocci, S.; Ceccacci, F.; Bombelli, C.; Di Vito, M.; Marchitiello, R.; Mariotti, M.; et al. Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective against Candida spp. Clinical Isolates. Int. J. Mol. Sci. 2022, 23, 2164. https://doi.org/10.3390/ijms23042164

AMA Style

Bugli F, Massaro F, Buonocore F, Saraceni PR, Borocci S, Ceccacci F, Bombelli C, Di Vito M, Marchitiello R, Mariotti M, et al. Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective against Candida spp. Clinical Isolates. International Journal of Molecular Sciences. 2022; 23(4):2164. https://doi.org/10.3390/ijms23042164

Chicago/Turabian Style

Bugli, Francesca, Federica Massaro, Francesco Buonocore, Paolo Roberto Saraceni, Stefano Borocci, Francesca Ceccacci, Cecilia Bombelli, Maura Di Vito, Rosalba Marchitiello, Melinda Mariotti, and et al. 2022. "Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective against Candida spp. Clinical Isolates" International Journal of Molecular Sciences 23, no. 4: 2164. https://doi.org/10.3390/ijms23042164

APA Style

Bugli, F., Massaro, F., Buonocore, F., Saraceni, P. R., Borocci, S., Ceccacci, F., Bombelli, C., Di Vito, M., Marchitiello, R., Mariotti, M., Torelli, R., Sanguinetti, M., & Porcelli, F. (2022). Design and Characterization of Myristoylated and Non-Myristoylated Peptides Effective against Candida spp. Clinical Isolates. International Journal of Molecular Sciences, 23(4), 2164. https://doi.org/10.3390/ijms23042164

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop